CTCL, including its leukemic variant Sézary syndrome, is characterized by a CD4+, CD45RO+ and CD8− phenotype and an elevated expression of constitutively active NFκB accompanied by resistance to PCD2, 20, 33. This evidence concerns the gene CD8A and primary cutaneous T-cell non-Hodgkin lymphoma.